vs
EXACT SCIENCES CORP（EXAS）与PROG Holdings, Inc.（PRG）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是PROG Holdings, Inc.的1.3倍（$878.4M vs $651.6M），PROG Holdings, Inc.净利率更高（5.5% vs -9.8%，领先15.3%），PROG Holdings, Inc.同比增速更快（457.1% vs 23.1%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 4.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
PROG Holdings是一家总部位于美国的金融科技企业，主要面向美国本土市场提供灵活的租购及销售点融资解决方案，核心业务涵盖零售合作伙伴融资、消费信贷与支付服务，帮助消费者无需满足传统信用要求即可购买电子产品、家居用品等商品。
EXAS vs PRG — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$651.6M
营收增速更快
PRG
高出434.0%
23.1%
净利率更高
PRG
高出15.3%
-9.8%
两年增速更快
EXAS
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $651.6M |
| 净利润 | $-86.0M | $36.1M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 10.0% |
| 净利率 | -9.8% | 5.5% |
| 营收同比 | 23.1% | 457.1% |
| 净利润同比 | 90.1% | 3.8% |
| 每股收益（稀释后） | $-0.45 | $3.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPRG
| Q1 26 | — | $651.6M | ||
| Q4 25 | $878.4M | $525.4M | ||
| Q3 25 | $850.7M | $595.1M | ||
| Q2 25 | $811.1M | $604.7M | ||
| Q1 25 | $706.8M | $684.1M | ||
| Q4 24 | $713.4M | $558.9M | ||
| Q3 24 | $708.7M | $606.1M | ||
| Q2 24 | $699.3M | $592.2M |
净利润EXASPRG
| Q1 26 | — | $36.1M | ||
| Q4 25 | $-86.0M | $40.5M | ||
| Q3 25 | $-19.6M | $33.1M | ||
| Q2 25 | $-1.2M | $38.5M | ||
| Q1 25 | $-101.2M | $34.7M | ||
| Q4 24 | $-864.6M | $57.5M | ||
| Q3 24 | $-38.2M | $84.0M | ||
| Q2 24 | $-15.8M | $33.8M |
毛利率EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASPRG
| Q1 26 | — | 10.0% | ||
| Q4 25 | -9.4% | 6.9% | ||
| Q3 25 | -3.0% | 9.0% | ||
| Q2 25 | -0.3% | 10.0% | ||
| Q1 25 | -13.6% | 8.2% | ||
| Q4 24 | -122.8% | 8.9% | ||
| Q3 24 | -5.6% | 8.1% | ||
| Q2 24 | -3.8% | 9.4% |
净利率EXASPRG
| Q1 26 | — | 5.5% | ||
| Q4 25 | -9.8% | 7.7% | ||
| Q3 25 | -2.3% | 5.6% | ||
| Q2 25 | -0.1% | 6.4% | ||
| Q1 25 | -14.3% | 5.1% | ||
| Q4 24 | -121.2% | 10.3% | ||
| Q3 24 | -5.4% | 13.9% | ||
| Q2 24 | -2.3% | 5.7% |
每股收益（稀释后）EXASPRG
| Q1 26 | — | $3.68 | ||
| Q4 25 | $-0.45 | $0.99 | ||
| Q3 25 | $-0.10 | $0.82 | ||
| Q2 25 | $-0.01 | $0.95 | ||
| Q1 25 | $-0.54 | $0.83 | ||
| Q4 24 | $-4.69 | $1.33 | ||
| Q3 24 | $-0.21 | $1.94 | ||
| Q2 24 | $-0.09 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $69.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $774.4M |
| 总资产 | $5.9B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPRG
| Q1 26 | — | $69.4M | ||
| Q4 25 | $964.7M | $308.8M | ||
| Q3 25 | $1.0B | $292.6M | ||
| Q2 25 | $858.4M | $222.0M | ||
| Q1 25 | $786.2M | $213.3M | ||
| Q4 24 | $1.0B | $90.9M | ||
| Q3 24 | $1.0B | $221.7M | ||
| Q2 24 | $946.8M | $250.1M |
总债务EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | — | $594.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $643.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXASPRG
| Q1 26 | — | $774.4M | ||
| Q4 25 | $2.4B | $746.4M | ||
| Q3 25 | $2.5B | $703.6M | ||
| Q2 25 | $2.5B | $668.7M | ||
| Q1 25 | $2.4B | $654.4M | ||
| Q4 24 | $2.4B | $650.3M | ||
| Q3 24 | $3.2B | $630.8M | ||
| Q2 24 | $3.2B | $581.9M |
总资产EXASPRG
| Q1 26 | — | $2.0B | ||
| Q4 25 | $5.9B | $1.6B | ||
| Q3 25 | $5.9B | $1.5B | ||
| Q2 25 | $5.8B | $1.5B | ||
| Q1 25 | $5.7B | $1.5B | ||
| Q4 24 | $5.9B | $1.5B | ||
| Q3 24 | $6.7B | $1.4B | ||
| Q2 24 | $6.7B | $1.5B |
负债/权益比EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $-54.9M | ||
| Q3 25 | $219.9M | $110.0M | ||
| Q2 25 | $89.0M | $69.9M | ||
| Q1 25 | $30.8M | $209.9M | ||
| Q4 24 | $47.1M | $-84.5M | ||
| Q3 24 | $138.7M | $31.9M | ||
| Q2 24 | $107.1M | $55.4M |
自由现金流EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $-57.5M | ||
| Q3 25 | $190.0M | $106.5M | ||
| Q2 25 | $46.7M | $68.0M | ||
| Q1 25 | $-365.0K | $208.0M | ||
| Q4 24 | $10.7M | $-86.8M | ||
| Q3 24 | $112.6M | $29.8M | ||
| Q2 24 | $71.2M | $53.5M |
自由现金流率EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | -10.9% | ||
| Q3 25 | 22.3% | 17.9% | ||
| Q2 25 | 5.8% | 11.2% | ||
| Q1 25 | -0.1% | 30.4% | ||
| Q4 24 | 1.5% | -15.5% | ||
| Q3 24 | 15.9% | 4.9% | ||
| Q2 24 | 10.2% | 9.0% |
资本支出强度EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 3.5% | 0.6% | ||
| Q2 25 | 5.2% | 0.3% | ||
| Q1 25 | 4.4% | 0.3% | ||
| Q4 24 | 5.1% | 0.4% | ||
| Q3 24 | 3.7% | 0.3% | ||
| Q2 24 | 5.1% | 0.3% |
现金转化率EXASPRG
| Q1 26 | — | — | ||
| Q4 25 | — | -1.36× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 1.82× | ||
| Q1 25 | — | 6.05× | ||
| Q4 24 | — | -1.47× | ||
| Q3 24 | — | 0.38× | ||
| Q2 24 | — | 1.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PRG
暂无分部数据
